Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Por um escritor misterioso
Descrição
In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.
Biomedicines, Free Full-Text
Therapeutic implications of menin inhibition in acute leukemias
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant
Revumenib trial meets complete remission endpoint for acute
Namrata Gautam on LinkedIn: T-cell Transfer Therapy - Immunotherapy
Frontiers Therapeutic targeting of leukemia stem cells in acute
Edward Carr on LinkedIn: Revumenib Shows Promise for Advanced
Heather LaGrande on LinkedIn: Pembrolizumab for Advanced Triple
Summary of in vitro and in vivo data of given compounds and
Clinical Trial Results National Cancer Institute
Therapeutic implications of menin inhibition in acute leukemias
Tana Takacova posted on LinkedIn
de
por adulto (o preço varia de acordo com o tamanho do grupo)
